AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver ...

The approval relies on positive data from the POTOMAC Phase III trial.

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

AstraZeneca announces CARES phase III clinical programme fails to meet primary endpoint in overall light chain amyloidosis population: Cambridge, UK Monday, June 1, 2026, 12:00 Hr ...

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...